

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

Granzyme B antibody

RRID:AB_304251

Type: Antibody

Proper Citation

Abcam Cat# ab4059, RRID:AB_304251

Antibody Information

URL: http://antibodyregistry.org/AB_304251

Proper Citation: Abcam Cat# ab4059, RRID:AB_304251

Target Antigen: Granzyme B antibody

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry - frozen; Flow Cytometry; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunohistochemistry - fixed; Flow Cyt, ICC/IF, IHC-FoFr, IHC-P
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Granzyme B antibody

Description: This polyclonal targets Granzyme B antibody

Target Organism: rat, mouse, human

Antibody ID: AB_304251

Vendor: Abcam

Catalog Number: ab4059

Record Creation Time: 20231110T081435+0000

Record Last Update: 20260901T063549+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Granzyme B antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Garczyk M, et al. (2026) Targeting PI3K γ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Cell reports, 45(4), 117188.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. Cancer cell, 44(6), 1179.

Wei S, et al. (2026) A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell reports. Medicine, 7(4), 102716.

Yue S, et al. (2026) Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Qin Y, et al. (2026) Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma. Nature communications, 17(1).

Srinivasan S, et al. (2025) Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3662.

Ding CH, et al. (2025) PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. Cell death & disease, 16(1), 158.

- Liu Y, et al. (2025) Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. *Cancer discovery*, 15(1), 162.
- Hu SW, et al. (2025) Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer. *Cell reports. Medicine*, 6(11), 102429.
- Ndjim M, et al. (2024) Tuft cell acetylcholine is released into the gut lumen to promote anti-helminth immunity. *Immunity*, 57(6), 1260.
- Yurkina DM, et al. (2024) The Interaction of HMGB1 with the Proinflammatory TREM-1 Receptor Generates Cytotoxic Lymphocytes Active against HLA-Negative Tumor Cells. *International journal of molecular sciences*, 25(1).
- Luckett T, et al. (2024) Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. *Cancer research*, 84(4), 527.
- Chibaya L, et al. (2024) Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. *Science translational medicine*, 16(762), eadj9366.
- Sakai Y, et al. (2023) Lethal severe fever with thrombocytopenia syndrome virus infection causes systemic germinal centre failure and massive T cell apoptosis in cats. *Frontiers in microbiology*, 14, 1333946.
- Chen H, et al. (2023) EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. *Cancer immunology research*, 11(6), 830.
- Lupo KB, et al. (2023) TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. *iScience*, 26(12), 108353.
- Watanabe S, et al. (2023) In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 37(11), e23228.
- Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.
- Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.